Meyer Andrew Hollman, an insider at Janux Therapeutics Inc (JANX), sold 84,974 shares of company stock on November 13, 2025, at a price of $30.00 per share. The total value of this transaction amounted to $2.55 million. Following this sale, Hollman retains 84,974 shares in the company.
Janux Therapeutics operates as a preclinical stage biopharmaceutical company headquartered in San Diego, California. It focuses on developing therapeutics through its Tumor Activated T Cell Engager platform technology. The company has created two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). Notable clinical candidates include JANX007, targeting prostate cancer, and JANX008, which is being studied for multiple solid cancers.
With a market capitalization of $1.6 billion and an EPS of -1.80, Janux Therapeutics is positioned in the biotechnology sector. Investors should note that insider transactions like Hollman’s can serve as a data point, but they should consider broader patterns of insider activity and other market factors before making decisions. Upcoming earnings are scheduled for May 5, 2026, with an estimated EPS of -0.74 and revenue of $224,400, followed by another report on August 4, 2026, estimating an EPS of -0.83 and revenue of $113,332.